Books and Book Chapters

      Lipidomics in Multi-Omics Studies

      Titz, B.; Lavrynenko, O.; Ivanov, N. V.

      Date published
      Mar 10, 2023
      DOI
      10.1002/9783527836512.ch23
      Published in
      Mass Spectrometry for Lipidomics: Methods and Applications
      Editors
      Holčapek, M.; Ekroos, K.
      Link to publication
      Topic
      Summary

      Lipidomics and integrative multi-omics methods are emerging rapidly. In this chapter, we highlight the role that lipidomics data can play in multi-omics studies. We exemplify how lipidomics data have contributed to insights in recent multi-omics studies. We describe specific considerations on the experimental methods and give an overview of relevant integrative computational analysis approaches. The experimental design must be adapted to the multi-omics context, and data analysis challenges must be considered. Finally, we summarize the great potential of lipidomics data in multi-omics and suggest ways in which the knowledge from such multimodal analysis sets can be further increased.

      Related Publications

      Impact of cigarette smoke and Modified Risk Tobacco Products (MRTPs) on DNA methylation

      Pre-clinical Toxicology Systems Toxicology

      Effects Of Cigarette Smoke On The High Fat Diet-Induced ApoE-/- Mouse Model Of Diabetic Atherosclerosis

      Pre-clinical Toxicology Systems Toxicology

      Chronological Changes in BEAS-2B Cells Chronically Exposed to Cigarette Smoke Total Particulate Matter

      Pre-clinical Toxicology Systems Toxicology

      Quantitative proteomics analysis using 2D-PAGE to investigate the effects of cigarette smoke and aerosol of a prototypic modified risk tobacco product on the lung proteome in C57BL/6 mice

      Pre-clinical Toxicology Systems Toxicology

      Anatabine ameliorates intestinal inflammation and reduces the production of pro-inflammatory factors in a dextran sulfate sodium mouse model of colitis

      Pre-clinical Toxicology Systems Toxicology

      The response of human nasal and bronchial organotypic tissue cultures to repeated whole cigarette smoke exposure

      Pre-clinical Toxicology Systems Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.